Search Results - "Genre, D."

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer by Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., Esterni, B., Genre, D., Moureau-Zabotto, L., Giovannini, M., Seitz, J-F., Delpero, J-R., Turrini, O., Viens, P., Raoul, J-L.

“…Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of…”
Get full text

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs by Faucher, C, Le Corroller Soriano, A G, Esterni, B, Vey, N, Stoppa, A M, Chabannon, C, Mohty, M, Michallet, M, Bay, J O, Genre, D, Maraninchi, D, Viens, P, Moatti, J P, Blaise, D

“…We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT…”
Get full text

Participants' uptake of clinical trial results: a randomised experiment by Mancini, J, Genre, D, Dalenc, F, Ferrero, J-M, Kerbrat, P, Martin, A-L, Roché, H, Maylevin, F, Tarpin, C, Viens, P, Genève, J, Julian-Reynier, C

“…Background: Participants are showing great interest these days in obtaining the results of clinical trials. The aim of this study was to assess patients’…”
Get full text

Patient participation in medical decision-making: A French study in adjuvant radio-chemotherapy for early breast cancer by Protière, C., Viens, P., Genre, D., Cowen, D., Camerlo, J., Gravis, G., Alzieu, C., Bertucci, F., Resbeut, M., Maraninchi, D., Moatti, J.-P.

“…Background: Shared decision-making is increasingly advocated as an ideal model. However, very few studies have tested the feasibility of giving patients the…”
Get full text

Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors by Gonçalves, A, Braud, A C, Viret, F, Genre, D, Gravis, G, Tarpin, C, Giovannini, M, Maraninchi, D, Viens, P

“…To determine the maximum tolerated dose of the combination of Carboplatin and Caelyx, a pegylated liposomal doxorubicin, with promising activities in various…”
Get more information

Docetaxel and radiotherapy and pancreatic cancer by VIRET, F, YCHOU, M, GENRE, D, MARANINCHI, D, VIENS, P, GIOVANNINI, M, GONCALVES, A, MOUTARDIER, V, MAGNIN, V, BRAUD, A. C, DUBOIS, J. B, BORIES, E, GRAVIS, G, CAMERLO, J

“…We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of weekly docetaxel delivered concurrently with radiation therapy for the treatment…”
Get full text

Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care by MACQUART-MOULIN, G, VIENS, P, BOUSCARY, M.-L, GENRE, D, RESBEUT, M, GRAVIS, G, CAMERLO, J, MARANINCHI, D, MOATTI, J.-P

“…Because side-effects of chemotherapy may be more diverse and patients' reactions more individualistic than tends to be acknowledged by clinicians, a survey was…”
Get full text

Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation by Chabannon, C, Le Corroller, A-G, Viret, F, Eillen, C, Faucher, C, Moatti, J-P, Viens, P, Vey, N, Braud, A-C, Novakovitch, G, Ladaique, P, Stoppa, A-M, Camerlo, J, Genre, D, Maraninchi, D, Blaise, D

“…Leukemia (2003) 17, 811-813. doi:10.1038/sj.leu.2402867…”
Get full text

Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study by VIRET, F, BERTUCCI, F, GENRE, D, GRAVIS, G, CHABANNON, C, CONTE, M, HOUVENAEGHEL, G, MARANINCHI, D, VIENS, P

“…From August 1995 to December 1997, 15 patients with stage III-IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell…”
Get full text

Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles by GENRE, D, PROTIERE, C, MACQUART-MOULIN, G, GRAVIS, G, CAMERLO, J, ALZIEU, C, MARANINCHI, D, MOATTI, J-P, VIENS, P

“…This study was designed to measure treatment side-effects and quality of life (QL) of 47 nonmetastatic breast cancer patients subjected to a dose-intensity…”
Get full text

Occult tumor cell contamination in patients with stage II III breast cancer receiving sequential high-dose chemotherapy by VIRET, F, CHABANNON, C, BARDOU, V. J, LADAIQUE, P, BRAUD, A. C, MARANINCHI, D, VIENS, P, SAINTY, D, GENRE, D, GONCALVES, A, ARNOULET, C, GRAVIS, G, BERTUCCI, F, HOUVENAEGHEL, G, JACQUEMIER, J

“…The purpose of this study was to evaluate the presence of micrometastatic cells in the apheresis products from patients with breast cancer, and also to…”
Get full text

Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics by Goncalves, A, Camerlo, J, Bun, H, Gravis, G, Genre, D, Bertucci, F, Resbeut, M, Pech-Gourg, F, Durand, A, Maraninchi, D, Viens, P

“…Preclinical and clinical data suggest a certain antitumor efficacy for combination of retinoids, cytokines and cytotoxic compounds. Between November 1994 and…”
Get more information

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens by GENRE, D, VIENS, P, PROTIERE, C, BARDOU, V-J, MARANINCHI, D, BERTUCCI, F, CHABANNON, C, GRAVIS, G, BRAUD, A-C, CAMERLO, J, HOUVENAEGHEL, G, MOUTARDIER, V, GONCALVEZ, A

“…The aim of this study was to evaluate and to compare in terms of toxicity the modulations of dose intensity of cyclophosphamide and doxorubicin in adjuvant…”
Get full text

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer by VIENS, P, GRAVIS, G, HOUVENAEGHEL, G, MARANINCHI, D, GENRE, D, BERTUCCI, F, COWEN, D, CAMERLO, J, CAPPIELLO, M.-A, CONTE, M, FINAUD, M, CHABANNON, C

“…The importance of dose-intensity has been suggested in breast cancer. The aim of this study was to evaluate the feasibility of a high-dose intensity…”
Get full text

Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide by Chabannon, C, Blache, J L, Sielleur, I, Douville, J, Faucher, C, Gravis, G, Arnoulet, C, Oziel-Taieb, S, Blaise, D, Novakovitch, G, Camerlo, J, Chabbert, I, Genre, D, Appel, M, Armstrong, D, Maraninchi, D, Viens, P

“…We report a clinical pilot study conducted in 6 women with poor-prognosis breast cancer. The goal was to evaluate the feasibility and safety of producing…”
Get more information

"They should take time": Disclosure of clinical trial results as part of a social relationship by Sarradon-Eck, Aline, Sakoyan, Juliette, Desclaux, Alice, Mancini, Julien, Genre, Dominique, Julian-Reynier, Claire

“…Disclosing overall scientific results to clinical trial participants has become an ethical obligation. Here we studied how participants understand these…”
Get full text

Décision de participer à un essai clinique en cancérologie: influence du vécu sur les attitudes by Mancini, J., Genève, J., Dalenc, F., Genre, D., Monnier, A., Kerbrat, P., Largillier, R., Serin, D., Rios, M., Roché, H., Jimenez, M., Tarpin, C., Julian-Reynier, C.

“…Résumé: L’objectif de cette étude était de comparer les attitudes théoriques par rapport à la participation ou non à un essai randomisé contrôlé (ERC) de trois…”
Get full text

Les mesures de la qualité de vie en cancérologie peuvent-elles changer la pratique des cliniciens ? by MACQUART-MOULIN, G, GENRE, D, MARANINCHI, D, VIENS, P

Get full text

Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma by Poizot-Martin, I, Giovannini, M, Rosello, R, Viallat, J R, Sauniere, J F, Dalmas, A M, Genre, D, Dhiver, C, Gastaut, J A

Get more information

The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell technology by Chabannon, C, Novakovitch, G, Blache, J L, Olivero, S, Camerlo, J, Genre, D, Maraninchi, D, Viens, P

“…In recent years, we have initiated two clinical studies, to evaluate the usefulness of ex-vivo expanded cells in patients with breast cancer who receive…”
Get more information